TY - JOUR
T1 - Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes
AU - Gonzalez-Quesada, Carlos
AU - Frangogiannis, Nikolaos G.
N1 - Funding Information:
This work was supported by National Institutes of Health grants R01 HL-76246 and R01 HL-76246.
PY - 2009
Y1 - 2009
N2 - The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.
AB - The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.
UR - http://www.scopus.com/inward/record.url?scp=60849117539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60849117539&partnerID=8YFLogxK
U2 - 10.1007/s11883-009-0021-y
DO - 10.1007/s11883-009-0021-y
M3 - Article
C2 - 19228487
AN - SCOPUS:60849117539
SN - 1523-3804
VL - 11
SP - 131
EP - 138
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 2
ER -